1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 32

    Enumeration of TBNK cells: A case for a bioanalytical assay to support clinical studies for the development of modified risk tobacco products

    NEWLAND K.; MILLER P.; FARMEN R.
    Celerion, Inc., Lincoln, NE, U.S.A.
    Smoking has been reported to lessen the body’s immune response making it more susceptible to infections. Chronic cigarette smoke exposure causes imbalance in immune homeostasis affecting the circulating immune cells. Peripheral blood lymphocytes are...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 17

    A clinical study investigating changes in exposure to cigarette smoke chemicals in U.K. smokers who switch to using a tobacco heating product for a five-day period

    McEWAN M.(1); EBAJEMITO J.K.(1); GALE N.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); MURPHY J.(1); HARDIE G.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) Celerion Inc., Lincoln, NE, U.S.A.
    Smoking is a leading cause of numerous diseases, particularly lung cancer, chronic obstructive pulmonary disease and cardiovascular diseases. Consequently, there is a recognized need to provide smokers with alternative nicotine-delivery devices that...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59

    An inter-laboratory comparison study focused on the determination of total NNAL in human urine

    NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
    (1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
    In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 61

    Novel biomarkers to characterize exposure to aldehydes from e-vapor products based on stable-isotope constituents

    LANDMESSER A.(1); SCHERER M.(1); SCHERER G.(1); SARKAR M.(2); EDMISTON J.S.(2); PLUYM N.(1)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    E vapor products (EVP) are an emerging category of non-combustible tobacco products that hold the promise of harm reduction for users of combustible products. Degradation products such as aldehydes have received much attention lately, however human...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 40

    Analytical methods for the determination of aldehydes in e-vapor aerosol and cigarette smoke and their urinary biomarkers of exposure

    LANDMESSER A.(1); SCHERER M.(1); SCHERER G.(1); SARKAR M.(2); EDMISTON J.S.(2); PLUYM N.(1)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services, Center for Research and Technology, Richmond, VA, U.S.A.
    Potential exposure to aldehydes, such as acrolein, formaldehyde or acetaldehyde, formed due to thermal degradation of the e-liquid constituents propylene glycol (PG) and glycerol (G) during the consumption of e-vapor products (EVPs), have received...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 23

    Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients – clinical study design

    SCHERER M.(1); LANDMESSER A.(1); PLUYM N.(1); SCHERER G.(1); SARKAR M.(2); EDMISTON J.(2)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    E-vapor products (EVPs) are becoming an accepted alternative to conventional cigarettes among smokers. Despite the increasing popularity of EVPs, little information exists on the fate of the main ingredients glycerol (G), propylene glycol (PG) and...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 24

    Biomarkers of exposure specific to e-vapour products based on stable-isotope labelled ingredients – results

    PLUYM N.(1); LANDMESSER A.(1); SCHERER M.(1); SCHERER G.(1); SARKAR M.(2); EDMISTON J.(2)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    E-vapor products (EVPs) consumption has steadily increased worldwide over the past decade. Ever since their introduction, there have been discussions about the potential health risks of EVPs in the scientific and public health community. These...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 43

    Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients – methods

    SCHERER M.(1); LANDMESSER A.(1); PLUYM N.(1); SCHERER G.(1); SARKAR M.(2); EDMISTON J.(2)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    E-vapor products (EVPs) are becoming an accepted alternative for nicotine delivery amongst smokers. The popularity of EVPs has been increasing and more systematic research is required in order to assess the impact of e-cigarette use-related exposure...